ORIENTBIO Submits FY2025 Audit Report: Operating Loss of 4.1 Billion Won, No Capital Impairment
ORIENTBIO received and disclosed its audit report on June 19, 2026. The auditor is KPMG Samjong Accounting Corp. with an unqualified opinion. No going concern uncertainty or internal control weaknesses were identified.
FY2025 financial highlights: total assets 81.6 billion won, total liabilities 13.1 billion won, total equity 68.5 billion won, and capital stock 59.3 billion won, with no capital impairment. Revenue was 29.7 billion won, a slight increase year-over-year, but operating loss was 4.1 billion won and net loss 4.6 billion won.
There were no capital changes such as equity issuance or convertible bonds in this audit report, and no shareholder return policies were disclosed.
[AI Summary]ORIENTBIO continues to post operating losses but is not in a capital impairment state, and the unqualified audit opinion ensures financial statement reliability. Investors should monitor profitability improvement and potential capital needs.